UNITED THERAPEUTICS Corp·4

Mar 11, 7:31 PM ET

ROTHBLATT MARTINE A 4

4 · UNITED THERAPEUTICS Corp · Filed Mar 11, 2026

Research Summary

AI-generated summary of this filing

Updated

United Therapeutics CEO Martine Rothblatt Exercises Options & Sells Shares

What Happened

  • Martine A. Rothblatt, Chairperson & CEO of United Therapeutics (UTHR), exercised 9,500 stock options on March 11, 2026 at $146.03 per share (total exercise cost $1,387,285) and then sold those 9,500 shares in multiple open-market trades the same day for aggregate proceeds of approximately $5,125,646. The filing shows the exercise (transaction code M) and multiple sales (S) that together represent a cashless exercise and immediate disposition under a pre-arranged plan.

Key Details

  • Transaction date: March 11, 2026.
  • Options exercised: 9,500 shares at $146.03 ($1,387,285).
  • Shares sold: 9,500 shares in multiple trades at prices ranging roughly $531.90–$544.94; weighted-average prices reported per tranche; total sales ≈ $5,125,646.
  • Net cash realized (sales minus exercise cost): ≈ $3,738,361 (before commissions/fees/taxes).
  • Notable footnote: Sales were made pursuant to a pre-arranged 10b5-1 trading plan adopted Nov 7, 2025 (F1). Several footnotes (F2–F13) note that specific sale tranches were executed in multiple trades and reported as weighted-average prices; detailed per-trade pricing is available on request.
  • Shares owned after transaction: not specified in the provided filing details.
  • Filing timeliness: filing and report date are both March 11, 2026 (appears timely).

Context

  • Code M indicates option exercise; because the exact same number of shares exercised were sold the same day under the 10b5-1 plan, this effectively operated as a cashless exercise (exercise + immediate sale).
  • The 10b5-1 plan is a pre-arranged program that allows insiders to sell shares at predetermined times; such sales are generally considered routine and not necessarily a direct signal of the insider’s current view on the company.
  • The reporting person offered to provide detailed per-trade share/price information to the SEC, issuer, or security holders as noted in the footnotes.

Insider Transaction Report

Form 4
Period: 2026-03-11
ROTHBLATT MARTINE A
DirectorChairperson & CEO
Transactions
  • Exercise/Conversion

    Common Stock

    [F1]
    2026-03-11$146.03/sh+9,500$1,387,2859,630 total
  • Sale

    Common Stock

    [F1][F2]
    2026-03-11$532.13/sh360$191,5669,270 total
  • Sale

    Common Stock

    [F1][F3]
    2026-03-11$533.47/sh240$128,0329,030 total
  • Sale

    Common Stock

    [F1][F4]
    2026-03-11$535.82/sh824$441,5128,206 total
  • Sale

    Common Stock

    [F1][F5]
    2026-03-11$536.95/sh1,215$652,3906,991 total
  • Sale

    Common Stock

    [F1][F6]
    2026-03-11$538.01/sh1,106$595,0405,885 total
  • Sale

    Common Stock

    [F1][F7]
    2026-03-11$538.92/sh1,095$590,1214,790 total
  • Sale

    Common Stock

    [F1][F8]
    2026-03-11$540.07/sh840$453,6583,950 total
  • Sale

    Common Stock

    [F1][F9]
    2026-03-11$541.04/sh942$509,6643,008 total
  • Sale

    Common Stock

    [F1][F10]
    2026-03-11$542.13/sh1,178$638,6311,830 total
  • Sale

    Common Stock

    [F1][F11]
    2026-03-11$543.04/sh240$130,3281,590 total
  • Sale

    Common Stock

    [F1][F12]
    2026-03-11$544.20/sh1,160$631,276430 total
  • Sale

    Common Stock

    [F1][F13]
    2026-03-11$544.76/sh300$163,428130 total
  • Exercise/Conversion

    Stock Option

    [F1]
    2026-03-119,500164,000 total
    Exercise: $146.03From: 2020-03-15Exp: 2027-03-15Common Stock (9,500 underlying)
Holdings
  • Common Stock

    (indirect: By Spouse)
    166
  • Common Stock

    [F14]
    (indirect: By Trust)
    324,518
  • Common Stock

    [F15]
    (indirect: By Trust)
    258,117
  • Common Stock

    [F16]
    (indirect: By Trust)
    45,596
  • Common Stock

    [F17]
    (indirect: By Trust)
    10,962
Footnotes (17)
  • [F1]This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026.
  • [F10]This transaction was executed in multiple trades at prices ranging from $541.56 to $542.55. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  • [F11]This transaction was executed in multiple trades at prices ranging from $542.64 to $543.47. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  • [F12]This transaction was executed in multiple trades at prices ranging from $543.66 to $544.50. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  • [F13]This transaction was executed in multiple trades at prices ranging from $544.68 to $544.94. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  • [F14]Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
  • [F15]Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
  • [F16]Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
  • [F17]Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
  • [F2]This transaction was executed in multiple trades at prices ranging from $531.90 to $532.31. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  • [F3]This transaction was executed in multiple trades at prices ranging from $533.04 to $533.69. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  • [F4]This transaction was executed in multiple trades at prices ranging from $535.42 to $536.41. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  • [F5]This transaction was executed in multiple trades at prices ranging from $536.44 to $537.39. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  • [F6]This transaction was executed in multiple trades at prices ranging from $537.46 to $538.44. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  • [F7]This transaction was executed in multiple trades at prices ranging from $538.46 to $539.40. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  • [F8]This transaction was executed in multiple trades at prices ranging from $539.52 to $540.45. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  • [F9]This transaction was executed in multiple trades at prices ranging from $540.56 to $541.54. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Signature
/s/ John S. Hess, Jr. under Power of Attorney|2026-03-11

Documents

1 file
  • 4
    primarydocument.xmlPrimary

    PRIMARY DOCUMENT